secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2026-06-29T13:00:16+00:00
Accession:  0001193125-26-286957
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026
---------------------------------------------------------------------------

- Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.
- Hyllengren receives $490k base salary, 40% target bonus, option to purchase 1.65M shares.
- SVP Finance Tomohiro Higa to retire in Q3 2026; will remain as consultant for transition.
- CEO Faraz Ali and Tomohiro Higa cease as interim PFO and acting PAO as of July 13.
- Hyllengren brings 20+ years experience in biotech finance, capital markets, corporate strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/0001193125-26-286957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/tnya-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer